Sinaptica’s neurostim treatment for Alzheimer’s wins FDA Breakthrough nod
Sinaptica Therapeutics announced today that it received FDA breakthrough device designation for its investigational SinaptiStim AD system.
Cambridge, Massachusetts-based Sinaptica designed its system to treat cognitive and functional decline in patients diagnosed with Alzheimer’s disease (AD).
The system creates a novel integration of neurostimulation and brain wave monitoring technologies. It combines those with a proprietary AI-derived personalization engine. Sinaptica said in a news release that SinaptiStim represents a new approach to treating patients suffering from dementia.
Under the FDA breakthrough program, Sinaptia receives priority regulatory review. The company can also maintain interactive communication with the FDA throughout the premarket review phase.
READ THE FULL ARTICLE HERE